Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the historic, yet short-lived, success of its Hepatitis C cures. However, as of early 2026, that narrative has shifted dramatically. Gilead has successfully executed a "second [...]
A director at one of the top clinical-stage biotech companies sold 6,000 insider shares towards the end of January 2026 amid the company's stock having an underwhelming performance in 2025.
As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is currently witnessing an unprecedented resurgence in Mergers and Acquisitions (M&A). This revival is being fueled by a
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
